Ceftriaxone

Ceftriaxonum

For medical students2 min readUpdated 2026-10-10

Ceftriaxone is a parenteral third-generation cephalosporin antibiotic. It features a broad antibacterial spectrum and the ability to cross the blood-brain barrier.

Drug ClassBeta-lactam antibiotics, third-generation cephalosporins.

Dosing RegimenLong half-life allows for once-daily administration.

Spectrum of ActivityHighly active against Neisseria gonorrhoeae and various other pathogens.

PharmacokineticsCrosses the blood-brain barrier effectively.

Mechanism of Action and Pharmacological Effects

As a beta-lactam antibiotic, ceftriaxone disrupts bacterial cell wall synthesis. Belonging to the third generation of cephalosporins, it exhibits potent activity against gram-negative bacilli. A key pharmacokinetic feature is its ability to cross the blood-brain barrier (BBB), making it a drug of choice for bacterial meningitis.

Indications

Ceftriaxone is the primary drug of choice for treating gonorrhea (Neisseria gonorrhoeae infections). It is also widely used for severe infections caused by susceptible organisms where high tissue and cerebrospinal fluid (CSF) concentrations are required.

Administration and Dosage

The drug is supplied as a powder for reconstitution (0.5–1.0 g). It is administered intramuscularly or intravenously (as a slow bolus over 2–4 minutes). Unlike cefotaxime, ceftriaxone requires administration only once daily, offering a significant pharmacokinetic advantage. The maximum daily dose is 4.0 g.

Adverse Effects and Risks

In patients with impaired renal clearance, there is a risk of drug accumulation, which increases the likelihood of toxicity. Dosage adjustment may be required in patients with combined renal and hepatic impairment.

Mnemonic

Ceftriaxone — "Tri" in the name: Trird generation, administered once daily (1x), effective for gonorrhea.

Frequently asked questions

What microorganisms are covered by ceftriaxone's spectrum of activity?

Ceftriaxone is active against a range of gram-negative and gram-positive bacteria. Documented activities include:

Gonococcus (Neisseria gonorrhoeae) — the causative agent of gonorrhea.
Shigella species — including multidrug-resistant strains.
Pseudomonas aeruginosa — activity is lower compared to ceftazidime and cefoperazone.

Ceftriaxone is used in streptococcal endocarditis and in combination with ampicillin for enterococcal endocarditis (though it lacks standalone activity against enterococci). P. aeruginosa isolates in cystic fibrosis possess intrinsic resistance to ceftriaxone.

For which conditions is ceftriaxone the drug of choice?

Ceftriaxone is the drug of choice for several specific infections and complications, including:

Gonorrhea — its primary clinical indication.
Meningitis — due to excellent blood-brain barrier penetration.
Streptococcal endocarditis — used in prolonged treatment courses.
Pelvic inflammatory disease (PID) — including cases complicated by bacteremia or arthritis.
Tick-borne viral encephalitis — when complicated by secondary bacterial infections or sepsis.
Liver cirrhosis — for antibiotic prophylaxis during acute variceal bleeding.

What adverse effects are associated with ceftriaxone?

Like other beta-lactams, ceftriaxone can cause several adverse reactions:

Allergic reactions — ranging from skin rashes to anaphylactic shock.
Gastrointestinal symptoms — various forms of dysbiosis or dyspepsia.
Neurotoxicity — seen mainly at high doses, manifesting as lowered seizure threshold.

Why is ceftriaxone preferred over cefotaxime for outpatient therapy?

Due to its longer half-life, ceftriaxone can be administered once daily, whereas cefotaxime requires multiple daily doses.

What is the risk of using ceftriaxone in renal failure?

Impaired renal function slows drug elimination, leading to accumulation and an increased risk of toxic adverse effects.

What is the role of ceftriaxone in meningitis treatment?

Ceftriaxone crosses the blood-brain barrier efficiently, achieving therapeutic concentrations in the CSF, which is critical for treating meningitis.

Go deeper

Comparative activity of third-generation cephalosporins against P. aeruginosa.
Mechanisms of beta-lactam resistance.
Pharmacokinetic differences between parenteral and oral cephalosporins.
Antibiotic selection strategies in patients with penicillin allergies.
The effect of inflammation on antibiotic tissue distribution.